TY - JOUR
T1 - The potential of sunitinib as a therapy in ovarian cancer
AU - Leone Roberti Maggiore, Umberto
AU - Valenzano Menada, Mario
AU - Venturini, Pier Luigi
AU - Ferrero, Simone
PY - 2013/12
Y1 - 2013/12
N2 - Introduction: Sunitinib malate (SU11248; Sutent®; Pfizer, Inc., New York) is a multi-kinase inhibitor currently approved for use in advanced renal cell carcinoma (RCC), imatinib-resistant/-intolerant gastrointestinal stromal tumours and progressive, well-differentiated pancreatic neuroendocrine tumours in patients with unresectable, locally advanced or metastatic disease. Areas covered: This article describes the mechanism of action and of the pharmacokinetics of sunitinib; further, it summarizes Phase I and II trials on the clinical efficacy, tolerability and safety of this agent in the setting of ovarian cancer (OC) treatment. Expert opinion: On the basis of the current literature, sunitinib has shown modest antitumour activity and acceptable toxicity. Studies investigating the impact of horizontal and vertical combinations should represent a priority of future research. Although clinical Phase II trials on the use of sunitinib in the treatment of OC demonstrated an acceptable profile of AEs, a greater comprehension of the toxicity of this compound is recommended.
AB - Introduction: Sunitinib malate (SU11248; Sutent®; Pfizer, Inc., New York) is a multi-kinase inhibitor currently approved for use in advanced renal cell carcinoma (RCC), imatinib-resistant/-intolerant gastrointestinal stromal tumours and progressive, well-differentiated pancreatic neuroendocrine tumours in patients with unresectable, locally advanced or metastatic disease. Areas covered: This article describes the mechanism of action and of the pharmacokinetics of sunitinib; further, it summarizes Phase I and II trials on the clinical efficacy, tolerability and safety of this agent in the setting of ovarian cancer (OC) treatment. Expert opinion: On the basis of the current literature, sunitinib has shown modest antitumour activity and acceptable toxicity. Studies investigating the impact of horizontal and vertical combinations should represent a priority of future research. Although clinical Phase II trials on the use of sunitinib in the treatment of OC demonstrated an acceptable profile of AEs, a greater comprehension of the toxicity of this compound is recommended.
KW - Efficacy
KW - Ovarian cancer
KW - Safety
KW - Sunitinib
KW - Tolerability
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84887633287&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887633287&partnerID=8YFLogxK
U2 - 10.1517/13543784.2013.841138
DO - 10.1517/13543784.2013.841138
M3 - Article
C2 - 24070205
AN - SCOPUS:84887633287
VL - 22
SP - 1671
EP - 1686
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
SN - 1354-3784
IS - 12
ER -